Market Research Logo

Canada Genetic Testing Market Outlook to 2024

Canada Genetic Testing Market Outlook to 2024

Summary

GlobalData’s new report, Canada Genetic Testing Market Outlook to 2024, provides key market data on the Canada Genetic Testing market. The report provides value, in millions of US dollars within market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

  • Market size and company share data for Genetic Testing market segments - Acquired Gene or Chromosome Alterations, Inborn Gene or Chromosome Alterations and Other Genetic Tests
  • Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2010 to 2017 and forecast to 2024.
  • 2017 company shares and distribution shares data for each of the market segments.
  • Global corporate-level profiles of key companies operating within the Canada Genetic Testing market.
  • Key players covered include F. Hoffmann-La Roche Ltd, Abbott Laboratories and Luminex Corp.
Reasons to buy
  • Develop business strategies by identifying the key market segments poised for strong growth in the future.
  • Develop market-entry and market expansion strategies.
  • Design competition strategies by identifying who-stands-where in the market.
  • Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
  • What are the key distribution channels and what’s the most preferred mode of product distribution - Identify, understand and capitalize.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 What Is This Report About?
2.2 Genetic Testing Market Segmentation
2.3 Definitions of Markets Covered in the Report
3 Genetic Testing Market, Canada
3.1 Genetic Testing Market, Canada, Revenue ($m), 2010-2017
3.2 Genetic Testing Market, Canada, Revenue ($m), 2017-2024
3.3 Genetic Testing Market, Canada, Distribution Share by Revenue ($m), 2017
3.4 Genetic Testing Market, Canada, Company Share by Revenue ($m), 2017
4 Overview of Key Companies in Canada, Genetic Testing Market
4.1 F. Hoffmann-La Roche Ltd
4.1.1 Company Overview
4.2 Abbott Laboratories
4.2.1 Company Overview
4.3 PerkinElmer Inc
4.3.1 Company Overview
4.4 Myriad Genetics Inc
4.4.1 Company Overview
4.5 Hologic Inc
4.5.1 Company Overview
4.6 Fujirebio Europe NV
4.6.1 Company Overview
4.7 Qiagen NV
4.7.1 Company Overview
5 Genetic Testing Market Pipeline Products
6 Financial Deals Landscape
6.1 Debt Offerings
6.1.1 GeneNews Raises USD0.7 Million in Private Placement of 8% Debentures Due 2019
6.2 Equity Offerings
6.2.1 3D Signatures to Raise up to USD2 Million in Private Placement of Units
6.2.2 3D Signatures Raises USD0.4 Million in Private Placement of Shares
6.3 Partnerships
6.3.1 Lucigen Enters into Distribution Agreement with Illumina
6.4 Venture Financing
6.4.1 GeneNews Raises USD0.2 Million in Venture Financing
7 Recent Developments
7.1 Corporate Communications
7.1.1 Oct 19, 2017: 3D Signatures Announces Changes to Its Board of Directors
7.1.2 Oct 10, 2017: 3D Signatures Announces Change to Its Board of Directors
7.1.3 Aug 11, 2017: 3D Signatures Announces Change to its Board of Directors
7.1.4 Jun 30, 2017: GeneNews Announces Election of Directors
7.1.5 May 05, 2017: 3D Signatures Announces Change to Its Board of Directors
7.1.6 Apr 11, 2017: 3D Signatures Announces Appointment of Dr. Kevin Little as Chief Scientific Officer
7.1.7 Feb 15, 2017: 3D Signatures Adds Medical Diagnostic Expert to Business Advisory Board
7.1.8 Jan 06, 2017: 3D Signatures Appoints Accomplished Healthcare Veteran as Chief Business Officer
7.1.9 Dec 09, 2016: 3D Signatures announces board changes
7.1.10 Dec 05, 2016: 3D Signatures appoints new member to 3DS' business advisory board
7.1.11 Nov 29, 2016: ARxIUM Introduces New RIVA Automated IV Compounding System
7.1.12 Nov 28, 2016: World Lung Conference Features Data Demonstrating Clinical Utility and Cost Effectiveness of Trovagene's Liquid Biopsy Tests for Mutation Detection and Monitoring in NSCLC Patients
7.1.13 Nov 28, 2016: Micell Technologies Announces First Patient Enrolled In Landmark Registration Trial Of MiStent In Japan
7.1.14 Nov 28, 2016: Konica Minolta Healthcare Introduces New Digital U-Arm Featuring Cutting-Edge Technology at RSNA 2016
7.1.15 Nov 28, 2016: MEDICREA Achieves Personalized Spine Milestone with 1,000 Patient-Specific UNiD Rod Procedures
7.1.16 Nov 28, 2016: Corsens Medical Announces Clearance of a 510(k) Pre-Marketing Notification with the US Food and Drug Administration for the Corsens Cardiac Monitor
7.1.17 Nov 14, 2016: 3D Signatures Introduces Internationally Recognized Clinical and Scientific Advisory Board
7.1.18 Oct 27, 2016: 3D Signatures Introduces Business Advisory Board and Celebrates Recent Listing by Opening Toronto Stock Exchange November 2
7.2 Financial Announcements
7.2.1 Oct 24, 2017: 3D Signatures Reports Financial Results for 2017
7.2.2 Aug 15, 2017: GeneNews Announces Q2-2017 Financial Results & Provides Progress Update
7.2.3 May 31, 2017: 3D Signatures Reports Third Quarter 2017 Financial Results
7.2.4 May 11, 2017: GeneNews Announces Q1-2017 Financial Results & Provides Progress Update
7.2.5 Apr 03, 2017: GeneNews Announces Fourth Quarter and Full Year 2016 Financial Results
7.2.6 Mar 02, 2017: 3D Signatures Reports Second Quarter 2017 Financial Results
7.2.7 Nov 11, 2016: GeneNews Announces Q3-2016 Financial Results and Provides Corporate Update
7.3 Legal And Regulatory
7.3.1 Sep 18, 2017: HTG Molecular Diagnostics Receives ISO 13485 Certification for Health Canada CMDCAS Requirements
7.3.2 Feb 06, 2017: OraSure Technologies Announces Settlement of Litigation with Ancestry.comDNA
7.4 Product News
7.4.1 Mar 14, 2017: 3D Signatures Makes Final Patent Payment
8 Appendix
8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Market Modeling and Forecasting
8.1.5 Company Share Analysis
8.1.6 Distribution Share Analysis
8.1.7 Benchmarking
8.2 GlobalData Consulting
8.3 Contact Us
8.4 Disclaimer
1.1 List of Tables
Table 1: Genetic Testing Market, Canada, Revenue ($m), USD Constant, Historic, 2010-2017
Table 2: Genetic Testing Market, Canada, Revenue ($m), USD Constant, Forecast, 2017-2024
Table 3: Genetic Testing Market, Canada, Distribution Share by Revenue ($m), USD Constant, 2017
Table 4: Genetic Testing Market, Canada, Company Share by Revenue ($m), USD Constant, 2017
Table 5: Genetic Testing Market Pipeline Products
Table 6: GeneNews Raises USD0.7 Million in Private Placement of 8% Debentures Due 2019
Table 7: 3D Signatures to Raise up to USD2 Million in Private Placement of Units
Table 8: 3D Signatures Raises USD0.4 Million in Private Placement of Shares
Table 9: Lucigen Enters into Distribution Agreement with Illumina
Table 10: GeneNews Raises USD0.2 Million in Venture Financing
Table 11: Total Number of Primary Research Participants, In Vitro Diagnostics Market, by Country
1.2 List of Figures
Figure 1: Genetic Testing Market, Canada, Revenue ($m), USD Constant, Historic, 2010-2017
Figure 2: Genetic Testing Market, Canada, Revenue ($m), USD Constant, Forecast, 2017-2024
Figure 3: Genetic Testing Market, Canada, Company Share (%) 2017

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report